

Guignardic Acid, a Novel Type of Secondary Metabolite Produced by the Endophytic Fungus *Guignardia* sp.: Isolation, Structure Elucidation, and Asymmetric Synthesis

by Katia F. Rodrigues-Heerklotz^a), Konstantin Drandarov^b), Jörg Heerklotz^b), Manfred Hesse^{*b}), and Christa Werner^{*b})

^a) Departamento de Micologia, Instituto Oswaldo Cruz, FIOCRUZ, CP 926, BR-21045-900, Rio de Janeiro, RJ, Brazil

^b) Organisch-chemisches Institut der Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich

A UV-guided fractionation of the AcOEt extract of the fermentation broth of *Guignardia* sp., an endophytic fungus from the leaves of the tropical tree *Spondias mombin*, resulted in the identification of the new metabolite (–)-(2*S*,5*Z*)-2-(1-methylethyl)-4-oxo-5-(phenylmethylene)-1,3-dioxolane-2-carboxylic acid (**1**), isolated as NH₄⁺ salt **1a**. The metabolite **1** was designated (–)-(S)-guignardic acid. This first member of a new class of natural compounds contains a dioxolanone moiety formed by fusion of 2-oxo-3-phenylpropanoic acid (phenylpyruvic acid) and 3-methyl-2-oxobutanoic acid (dimethylpyruvic acid), products of the oxidative deamination of phenylalanine and valine, respectively. The structure of **1a** was deduced from spectral data (UV, IR, MS, ¹H- and ¹³C-NMR) and confirmed by asymmetric synthesis.

Introduction. – The interest in endophytic fungi as a source of novel bioactive compounds is increasing mainly because of the difficulty to find new interesting lead compounds from extensively investigated organisms. In Brazil, *Spondias mombin* L. (Anacardiaceae) has been used in traditional medicine because of its antimicrobial properties [1].

Species of *Guignardia* (Ascomycetes) and/or its anamorph genus *Phyllosticta* have been frequently isolated as endophytes [2–4]. *Phyllosticta*, a genus of asexual fungi, is a source of various secondary metabolites. The most abundant, the phytotoxin phyllosinol, containing an α,β -unsaturated ketone moiety, shows antibacterial activity [5][6]. Recently the sesquiterpene lactone heptelidic acid and two analogues, which are toxic against spruce budworm larvae, have been reported [7].

During an initial screening of secondary metabolites produced by strains of different fungal species isolated as endophytes from *S. mombin* that could contain useful antimicrobial properties [8], we selected a *Guignardia* strain based on some degree of antibacterial activities demonstrated by its crude extract. In the present communication, we describe the isolation, structure elucidation, and asymmetric synthesis of the new metabolite (–)-(S)-guignardic acid (**1**) as ammonium salts **1a** or **1b**.

Results and Discussion. – (–)-(S)-Guignardic acid (**1**), isolated as its NH₄⁺ salt **1a**, was obtained as amorphous solid and identified as (–)-(2*S*,5*Z*)-2-(1-methylethyl)-4-oxo-5-(phenylmethylidene)-1,3-dioxolane-2-carboxylic acid, as deduced from UV, IR, MS, ¹H-, ¹³C-NMR spectral data.

We failed to obtain useful data of **1** by the usual positive mode in EI, CI, or ESI mass spectrometric methods, but the ESI-MS data of ammonium guignardate **1a** in the negative mode furnished a [M – H][–] peak at

m/z 261 (molecular mass 262 for $C_{14}H_{14}O_5$). The tandem mass spectrum (MS/MS) from the parent ion at m/z 261 showed two daughter ions: one at m/z 217, which obviously arises by loss of CO_2 , and one at m/z 189 (the base fragment ion), which can be written as $[M - H - CO_2 - CO]^-$.


The UV spectrum of the salt **1a**, showing a strong absorption band at 301 nm, is similarly shaped as those of (*E*)-cinnamic acid derivatives and suggests a similarly arranged extended chromophore system. The presence of the strong bands at 1646 and 1783 cm^{-1} in the IR spectrum of **1a**, corresponding to conjugated C=C and C=O bonds, supports such a correlation. Moreover, the strong shorter wavelength shift (at 1783 cm^{-1}) of the second band indicates that the corresponding C=O group is part of a five-membered lactone ring. In addition, the IR spectrum of **1a** contains a broad band at 3404 cm^{-1} (OH) and a strong band at 1666 cm^{-1} (C=O), which evidently belong to a COOH group.

The ^{13}C -NMR spectrum of **1a** confirms the presence of two C=O groups at $\delta(C)$ 166.5 and 164.6, one olefinic methin CH at $\delta(C)$ 104.0, and two quaternary C-atoms of which one is an olefinic ($\delta(C)$ 139.1) and the other a quaternary acetal C-atom ($\delta(C)$ 111.0). The lack of spin-spin coupling of the signal at $\delta(H)$ 6.22 (*s*) is evidence that the corresponding olefinic CH group is located between two quaternary C-atoms and is part of a conjugated, exocyclic C=C bond. The signals for one methine C-atom ($\delta(C)$ 31.6 and $\delta(H)$ 2.62 (*sept.*), together with the signals for two Me groups ($\delta(C)$ 16.4 and 15.1 ppm and the *d* at $\delta(H)$ 0.92 and 0.95, resp.) indicate the presence of an isopropyl moiety in **1a**. The *d* at $\delta(H)$ 7.66 and two *t* at $\delta(H)$ 7.38 and 7.27 in the 1H -NMR spectrum of **1a** are typical of a mono-substituted benzene ring. The structure elucidation of (–)-guignardic acid (**1**) was further supported by 2D NMR experiments (DEPT, HSQC, and HMBC). In addition, the presence of the strong UV absorption band at 301 nm, typical for the (*E*)-cinnamic acid chromophore is evidence for the (*Z*)-configuration of the exocyclic double bond of **1** [9][10].

To confirm the structural conclusions described above and to establish its absolute configuration, (–)-(*S*)-guignardic acid (**1**) was asymmetrically synthesized, as shown in *Scheme 1*. Starting from benzyl 3-methyl-2-oxobutanoate (**3**) (obtained from the commercially available sodium 3-methyl-2-oxobutanoate (**2**) and phenylmethanol in the presence of $SOCl_2$) and commercially available (*2R*)-2-hydroxy-3-phenylpropanoic acid (**4**) in the presence of $BF_3 \cdot Et_2O$ [11], the 6:1 mixture of the diastereoisomeric dioxolanones **5** and **6** was prepared in 48% yield similarly to a published procedure. The mixture was separated by CC. The (*2S,5R*)-configuration of **5** was established by a NOESY experiment (NOE between Me_2CH and $PhCH_2-C(5)$). Similarly, the (*2R,5R*)-configuration was deduced for the diastereoisomer **6** (NOE between Me_2CH and $H-C(5)$). According to a procedure used for similar compounds [12], diastereoisomer **5** was refluxed for 10 min in the presence of *N*-bromosuccinimide (NBS) and a catalytic amount of 2,2'-azobis[isobutyronitrile] (AIBN) in CCl_4 under irradiation with white light to give the brominated derivative **7** in 45% yield. The NOESY experiment of **7** confirmed its (*2R,4S*)-configuration (NOE between both Me of Me_2CH and arom. H-atoms of $PhCH_2-C(5)$). Thus, the bromination of **5** at C(5) proceeded in a strictly stereoselective manner with retention of configuration. The elimination of HBr from compound **7** carried out in acetone in the presence of Et_3N , similarly to a published procedure [12], yielded ester **8** quantitatively. By selective catalytic hydrogenolysis in the presence of *Lindlar* catalyst, compound **8** was transformed to (–)-(*S*)-guignardic acid (**1**) almost quantitatively. Because of its instability under acidic conditions, the synthetically prepared **1** was isolated as its triethylammonium salt **1b**. The synthetic triethylammonium (–)-(*S*)-guignardate (**1b**) was identical to the natural ammonium salt **1a** by TLC, HPLC (t_R), UV, and chiroptical properties (*Fig.*), including its absolute configuration¹⁾.

¹⁾ The differences between the 1H -NMR chemical shifts of the natural (isolated as ammonium salt **1a**) and synthetic (–)-(*S*)-guignardic acid (prepared as triethylammonium salt **1b**) are a function of the different cationic counterparts.

Scheme 1



To the best of our knowledge, (-)-(S)-guignardic acid (**1**) is the first identified member of a new class of natural compounds. Obviously, the biogenetic precursors of **1** are 3-methyl-2-oxobutanoic acid (dimethylpyruvic acid; **9**) and 2-oxo-3-phenylpropanoic acid (phenylpyruvic acid; **10**), which are products of the oxidative deamination of the amino acids valine and phenylalanine, respectively. The proposed biogenetic pathway of these compounds is shown in *Scheme 2*. The existence of other combinations of naturally occurring keto acids derived from deaminated α -amino




Figure 1. CD Spectrum of *(-)*-(2*S*)-guignardic acid ammonium salt (**1a**)

acids is likely. It is known that phenylpyruvic acid exists mainly in its enol-tautomer form **10b**. Obviously the tautomerism of phenylpyruvic acid makes it a favored reaction partner in the formation of such natural dioxolanones.

The authors are grateful to Mr. *Martin Binder* of our NMR Department for the measurements and assistance during the interpretation of the NMR spectra of the natural guignardic acid and to Drs. *Laurent Bigler* and *Aycil Yurdakul* for the MS measurements. This study was supported in part by a *Grant-in-Aid for Scientific Research* from the *Brazilian National Council for Scientific and Technological Research (CNPq)*, the *Swiss National Science Foundation*, and the *Dr. Helmut Legerlotz-Stiftung*.

(s, 1 H); 2.62 (sept., $J = 6.8$, 1 H); 0.95 (d , $J = 6.9$, 1 Me); 0.92 (d , $J = 6.9$, 1 Me). $^{13}\text{C-NMR}$ ($(\text{D}_6$)DMSO): 166.5 (C=O); 164.6; 139.1; 111.0; 133.3; 129.1; 128.8; 128.1; 104.0; 31.6; 15.1; 16.4. ESI-MS: 261 ($[\text{M} - \text{H}]^-$, $[\text{C}_{14}\text{H}_{14}\text{O}_5 - \text{H}]^-$). ESI-MS/MS ($-\text{DAU}$ 261, 8 eV): 261 (36, $[\text{M} - \text{H}]^-$), 217 (2, $[\text{M} - \text{H} - \text{CO}_2]^-$), 189 (100, $[\text{M} - \text{H} - \text{CO}_2 - \text{CO}]^-$).

Phenylmethyl 3-Methyl-2-oxobutanoate (**3**). To a suspension of sodium 3-methyl-2-oxobutanoate (**2**; 3.4 g) in phenylmethanol (12 ml), SOCl_2 (2.9 ml) was added dropwise at 0° . The mixture was stirred at 0° for 30 min. After addition of H_2O (20 ml), the mixture was stirred for 10 min and then extracted with AcOEt. The org. layer was washed with aq. Na_2CO_3 soln. and H_2O and evaporated. The residual oil was purified by CC (silica gel, hexane, then hexane/THF 10:0.5): **3** (3.7 g, 82%). Colorless oil. TLC (hexane/THF 19:1): R_f 0.4. $^1\text{H-NMR}$ (CDCl_3): 7.5–7.25 (m , 5 arom. H); 5.28 (s , PhCH_2O); 3.24 (m , $J = 6.9$, Me_2CH); 1.14 (d , $J = 6.9$, Me_2CH). $^{13}\text{C-NMR}$ (CDCl_3): 197.74 (C=O); 161.60 (ester, C=O); 134.53 (arom. quat. C); 128.59, 128.43, 128.28, 127.66 (arom. C); 67.58 (COOCH_2Ph); 37.07 (Me_2CH); 16.98 (Me). EI-MS: 205 (3, $[\text{M} - \text{H}]^+$), 91 (100, C_7H_7^+).

Phenylmethyl (2S,5R)-2-(1-Methylethyl)-4-oxo-5-(phenylmethyl)-1,3-dioxolane-2-carboxylate (**5**). A mixture of commercially available (2R)-2-hydroxy-3-phenylpropanoic acid (**4**; 2 g, 0.012 mol), **3** (1.27 g, 0.006 mol), and 48% $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (6 ml) was stirred for 2 h at r.t., then diluted with CH_2Cl_2 , and carefully transferred by small portions to a separatory funnel containing aq. Na_2CO_3 soln. After every portion, the funnel was carefully shaken until the liberation of CO_2 was finished. The aq. phase was extracted once more with CH_2Cl_2 , the combined org. extract washed with H_2O and evaporated, and the residue dissolved in toluene (5 ml) and Et_3N (1.5 ml) and purified by CC (silica gel, hexane, then hexane/THF 10:0.5): **5** (1 g, 48%). Colorless oil. TLC (hexane/THF 19:1): R_f 0.3 (**6**: R_f 0.27). $[\alpha]_D^{25} = +12$ ($c = 2.38$, CHCl_3). $^1\text{H-NMR}$ (CDCl_3): 7.45–7.15 (m , 10 arom. H); 5.21 (s , PhCH_2O); 4.67, 4.66 ($2d$, $J = 6.8$, 4.2, $\text{H}-\text{C}(5)$); 3.21, 3.2 ($2d$, $J = 14.7$, 4.2, 1 H, PhCH_2CH); 3.07, 3.04 ($2d$, $J = 14.7$, 6.8, 1 H, PhCH_2CH); 2.37 (m , $J = 6.9$, Me_2CH); 0.81 (d , $J = 6.9$, Me_2CH). $^{13}\text{C-NMR}$ (CDCl_3): 171.5, 166.7 (2 C=O); 135.21, 134.56 (2 arom. quat. C); 129.56, 128.59, 128.41, 128.10, 127.04 (arom. C); 107.98 (C(2)); 75.75 (C(5)); 67.75 (COOCH_2Ph); 36.79 (PhCH_2CH); 31.63 (Me_2CH); 15.17, 14.62 (Me_2CH). EI-MS: 313 (40, $[\text{M} - \text{CH}_2 = \text{CHCH}_2]^+$), 219 (28, $[\text{M} - \text{PhCH}_2\text{OCO}]^+$), 191 (20, $[\text{M} - \text{PhCH}_2\text{OCO} - \text{C}=\text{O}]^+$), 91 (100, C_7H_7^+).

Phenylmethyl (2R,4S)-4-Bromo-2-(1-methylethyl)-5-oxo-4-(phenylmethyl)-1,3-dioxolane-2-carboxylate (**7**). To a soln. of **5** (0.86 g, 0.0024 mol) in CCl_4 (5 ml), NBS (0.44 g, 0.0027 mol) and AIBN (12 mg) were added. The pale yellow suspension was refluxed for 10 min under irradiation with white light (normal-pressure 200-W lamp, placed at ca. 30 cm from the reaction flask) to give a colorless suspension²⁾. The mixture was diluted with CCl_4 , the insoluble succinimide removed by filtration, and the filtrate washed with sat. aq. NaHCO_3 soln. and evaporated. The residual oil was dissolved in a few ml of hexane containing a few drops of THF and separated by CC (hexane/THF 10:0.5): **7** (470 mg, 45%)³⁾. Colorless oil. TLC (hexane/THF 19:1): R_f 0.4. $[\alpha]_D^{25} = -63$ ($c = 0.88$, CHCl_3). $^1\text{H-NMR}$ (CDCl_3): 7.45–7.15 (m , 10 arom. H); 5.27 (s , PhCH_2O); 3.81 (s , PhCH_2CBr); 1.99 (m , $J = 6.9$, Me_2CH); 0.7 (d , $J = 6.9$, 3 H, Me_2CH); 0.36 (d , $J = 6.9$, 3 H, Me_2CH). $^{13}\text{C-NMR}$ (CDCl_3): 165.66, 165.49 (2 C=O); 134.15, 133.10 (2 arom. quat. C); 128.79, 128.67, 128.56, 128.50, 127.98 (arom. C); 107.96 (C(2)); 88.45 (CBr); 68.36 (COOCH_2Ph); 46.32 (PhCH_2CBr); 33.51 (Me_2CH); 15.37, 13.66 (Me_2CH). EI-MS: 352 (4, $[\text{M} - \text{HBr}]^+$), 297 (20, $[\text{M} - \text{PhCH}_2\text{OCO} - \text{H}]^+$), 217 (20, $[\text{M} - \text{PhCH}_2\text{OCO} - \text{HBr}]^+$), 91 (100, C_7H_7^+).

Phenylmethyl (2S,5Z)-2-(1-Methylethyl)-4-oxo-5-(phenylmethylene)-1,3-dioxolane-2-carboxylate (**8**). To a soln. of **7** (100 mg) in acetone (4 ml), Et_3N (1 ml) was added at r.t. The mixture was stirred for 2 h (\rightarrow crystals of $\text{Et}_3\text{N} \cdot \text{HBr}$). The solvent was evaporated, the residue dissolved in toluene, the insoluble $\text{Et}_3\text{N} \cdot \text{HBr}$ filtered off, and the filtrate separated by CC (hexane, then hexane/THF 50:1): **8** (80 mg, quant.). Colorless, glass-like residue. TLC (hexane/THF 19:1): R_f 0.4. $[\alpha]_D^{25} = -142$ ($c = 0.59$, CHCl_3). $^1\text{H-NMR}$ (CDCl_3): 7.8–7.15 (m , 10 arom. H); 6.49 (s , $\text{PhCH}=\text{C}$); 5.26 (s , PhCH_2O); 2.68 (m , $J = 6.9$, Me_2CH); 1.04 (d , $J = 6.9$, Me_2CH). $^{13}\text{C-NMR}$ (CDCl_3): 165.17, 152.75 (2 C=O); 135.66, 134.43, 132.15 (2 arom. + 1 olef. quat. C); 129.79, 128.96, 128.65, 128.53, 127.90 (arom. C); 109.59 (olef. C); 108.4 (C(2)); 68.02 (COOCH_2Ph); 32.72 (Me_2CH); 15.12, 14.36 (Me_2CH). CI-MS: 370 (100, $[\text{M} + \text{NH}_3 + \text{H}]^+$), 352 (10, $\text{M}^{+\cdot}$).

Triethylammonium (2S,5Z)-2-(1-Methylethyl)-4-oxo-5-(phenylmethylene)-1,3-dioxolane-2-carboxylate (**1b**). To a suspension of 10% Pd/C (35 mg) in toluene (2.5 ml), a 0.25% soln. of quinoline (0.67 ml) in toluene and a soln. of **8** in toluene (100 mg in 2 ml) were added. The suspension was stirred 2 h at r.t. under H_2 .

2) Sometimes, the bromination reaction worked poorly; the introduction of a few drops of diluted Br_2 soln. in CCl_4 to the starting suspension helped in these cases.

3) Because of additional bromination of **5** at the benzyl ester CH_2 group and following hydrolysis, some benzaldehyde was formed, which was eluted just before.

Then, Et₃N (0.5 ml) was added, the catalyst filtered off, and the filtrate evaporated (bath temp. < 45°): **1b** (96 mg, 93%). Viscous, colorless oil. TLC (CHCl₃/MeOH/25% aq. NH₃ soln. 8:2:0.3): R_f 0.2. [α]_D = –92 (c = 1.8, MeOH). ¹H-NMR ((D₆)DMSO): 7.69 (*d*, *J* = 7.6, 2 arom. H); 7.6–7.2 (*m*, 3 arom. H); 6.3 (*s*, 1 olef. H); 3.15 (*q*, *J* = 7.3, (MeCH₂)₃N); 2.72 (*m*, *J* = 6.9, Me₂CH); 1.23 (*t*, *J* = 7.3, (MeCH₂)₃N); 1.05 (*t*, *J* = 6.9, Me₂CH). ¹³C-NMR ((D₆)DMSO): 166.43, 163.83 (2 C=O); 138.02, 132.83 (2 arom. quat. C); 129.55, 128.95, 128.53, 128.06 (arom. C); 110.09 (C(2)); 104.84 (olef. CH); 45.21 ((MeCH₂)₃N); 31.35 (Me₂CH); 15.76, 14.73 (Me₂CH); 8.26 ((Me(CH₂)₃N). ESI-MS: 102 (100, Et₃NH⁺), 364 (20, [M + Et₃N + H]⁺), 386 (40, [M + Et₃N + Na]⁺).

REFERENCES

- [1] J. Corthout, L. Pieters, M. Claeys, D. A. Vanden Berghe, A. J. Vlietinck, *Phytochemistry* **1991**, *30*, 1129.
- [2] O. Petrini, J. Stone, F. E. Carroll, *Can. J. Bot.* **1982**, *60*, 789.
- [3] J. A. Johnson, N. J. Whitney, *Can. J. Bot.* **1989**, *67*, 723.
- [4] A. Leuchtmann, O. Petrini, L. Petrini, G. C. Carroll, *Mycol. Res.* **1992**, *96*, 287.
- [5] R. Sakai, R. Sato, H. Niki, S. Sakamura, *Plant Cell Physiol.* **1970**, *11*, 907.
- [6] S. Sakamura, J. Ito, R. Sakai, *Agr. Biol. Chem.* **1971**, *35*, 105.
- [7] L. A. Callhoun, J. A. Findlay, J. D. Miller, N. J. Whitney, *Mycol. Res.* **1992**, *96*, 281.
- [8] K. F. Rodrigues, M. Hesse, C. Werner, *J. Basic Microbiol.* **2000**, *40*, 261.
- [9] H.-J. Brunk, H. Fritz, E. Hädicke, *Chem. Ber.* **1983**, *116*, 2165.
- [10] R. Ramage, G. J. Griffiths, F. E. Shutt, J. N. A. Sweeney, *J. Chem. Soc., Perkin Trans. I*, **1984**, 1531.
- [11] M. Farines, J. Soulier, *Bull. Soc. Chim. Fr.* **1970**, 332.
- [12] G. Schwenker, K. Stiefvater, *Arch. Pharm. (Weinheim)* **1991**, *324*, 307.
- [13] K. F. Rodrigues, G. J. Samuels, *J. Basic Microbiol.* **1999**, *39*, 131.

Received June 20, 2001